N
Novo Nordisk A/S (NVO)
NYQ – Real Time Price. Currency in USD
47.00
+0.60 (1.29%)
At close: May 12, 2026, 4:00 PM EDT
47.45
+0.47 (1.00%)
Pre-market: May 13, 2026, 7:29 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NYQ – Real Time Price. Currency in USD
47.00
+0.60 (1.29%)
At close: May 12, 2026, 4:00 PM EDT
47.45
+0.47 (1.00%)
Pre-market: May 13, 2026, 7:29 AM EDT
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Name | Position |
|---|---|
| Dr. Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board |
| Mr. Emil Kongshoej Larsen | EVP of International Operations & Member of Management Board |
| Mr. Jamey Millar | Executive VP of US Operations & Member of Management Board |
| Mr. John F. Kuckelman | SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board |
| Mr. Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board |
| Mr. Maziar Mike Doustdar B.A. | President, CEO & Member of the Management Board |
| Ms. Elin Jager | SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board |
| Ms. Hong Chow | Executive VP of Product & Portfolio Strategy and Member of Management Board |
| Ms. Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board |
| Ms. Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 6-K | caq12026.htm |
| 2026-05-05 | 6-K | f6k_050526.htm |
| 2026-04-27 | 6-K | f6k_042726.htm |
| 2026-04-20 | 6-K | f6k_042026.htm |
| 2026-04-13 | 6-K | f6k_041326.htm |
| 2026-04-07 | 6-K | f6k_040726.htm |
| 2026-03-30 | 6-K | f6k_033026.htm |
| 2026-03-27 | 6-K | f6k_032726.htm |
| 2026-03-26 | 6-K | f6k_032626.htm |
| 2026-03-23 | 6-K | f6k_032326.htm |